Valuation: Krystal Biotech, Inc.

Market Cap 10.26B 8.78B 8.22B 7.52B 14.15B 982B 14.31B 97.05B 37.82B 493B 38.52B 37.68B 1,630B P/E 2026 *
45.7x
P/E 2027 * 37x
Enterprise Value 10.26B 8.78B 8.22B 7.52B 14.15B 982B 14.31B 97.05B 37.82B 493B 38.52B 37.68B 1,630B EV / Sales 2026 *
20x
EV / Sales 2027 * 15.7x
Free-Float
89.17%
Yield 2026 *
-
Yield 2027 * -
1 day+2.84%
1 week+4.31%
Current month+1.60%
1 month+2.90%
3 months+15.74%
6 months+32.38%
Current year+40.58%
1 week 330.06
Extreme 330.06
348.03
1 month 297.02
Extreme 297.02
369
Current year 235.6
Extreme 235.605
382.54
1 year 136.73
Extreme 136.73
382.54
3 years 93.95
Extreme 93.95
382.54
5 years 38.86
Extreme 38.8563
382.54
10 years 8.03
Extreme 8.03
382.54
Manager TitleAgeSince
Chief Operating Officer 61 2016-04-14
Chief Executive Officer 61 2016-04-14
Investor Relations Contact - -
Director TitleAgeSince
Chairman 61 2016-04-14
Director/Board Member 61 2016-04-14
Director/Board Member 60 2016-10-31
Date Insider Type Main position Quantity % Market Cap.
8/14/26 Don

Director

-28,691 0.0973%
3/1/26 Other

EVP, Head of International

51,478 0.1761%
3/1/26 Other

General Counsel

68,165 0.2332%
Change 5-day change 1-year change 3-year change Capi.($)
+2.84%+4.31%+130.31%+177.53% 10.26B
+0.90%+3.80%+41.49%-0.78% 83.28B
+8.86%+129.20%+435.14%+24.85% 57.94B
-1.69%+23.30%-22.30%-36.29% 57.77B
-1.46%+0.19%-2.06%+30.50% 51.75B
+1.74%+4.43%+12.37%+169.64% 49.35B
+1.13%+3.31%+55.61%-17.57% 32.03B
+0.46%+6.37%+50.29%+97.27% 25.91B
+1.19%+9.17%+2.97%+230.86% 22.74B
-0.30%+4.45%+58.29%+118.84% 16.87B
Average +1.37%+18.85%+76.21%+79.49% 40.79B
Weighted average by Cap. +1.47%+24.46%+81.77%+49.67%

Financials

2026 *2027 *
Net sales 513M 439M 411M 376M 707M 49.05B 715M 4.85B 1.89B 24.63B 1.92B 1.88B 81.46B 655M 560M 524M 480M 903M 62.63B 913M 6.19B 2.41B 31.45B 2.46B 2.4B 104B
Net income 237M 203M 190M 174M 327M 22.71B 331M 2.25B 875M 11.4B 891M 872M 37.72B 307M 263M 246M 225M 423M 29.33B 428M 2.9B 1.13B 14.73B 1.15B 1.13B 48.72B
Net Debt - -
Logo Krystal Biotech, Inc.
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Employees
295
Date Price Change Volume
26-08-21 US$346.58 +2.84% 407,806
26-08-20 US$337.02 -1.84% 196,703
26-08-19 US$343.34 +3.16% 162,843
26-08-18 US$332.82 -0.87% 148,469
26-08-17 US$335.73 +1.04% 255,136
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
346.58USD
Average target price
385.00USD
Spread / Average Target
+11.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KRYS Stock